Boston Scientific shares fell by 1.97% on the latest trading day even as the broader healthcare index gained 1.3%, marking the stock’s third consecutive decline. Volume on Boston Scientific was 12% above its 30-day average, suggesting profit-taking after a 14% rally over the past two months. Analysts attribute the pullback in part to cautious positioning ahead of the company’s full-year guidance update scheduled for next week. Institutional holders reduced exposure by an estimated 0.4 percentage points over the past five trading sessions, according to fund‐flow data, while short interest ticked up 5% as investors awaited clarity on margins in the company’s newer electrophysiology and peripheral intervention franchises.